Alector to Host Mid-Year Earnings Conference Call

7/31/24 4:05:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ALEC alert in real time by email

SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2024, and provide a mid-year business update. A press release detailing second quarter results will be issued prior to the call.

The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events, and following the event, a replay will be archived there for 30 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Alector

Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain's immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector's immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer's disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Alector Contacts:

Alector

Katie Hogan

202-549-0557

[email protected]

1AB (media)

Dan Budwick

973-271-6085

[email protected]

Argot Partners (investors)

Laura Perry

212.600.1902

[email protected]

Get the next $ALEC alert in real time by email

Recent Analyst Ratings for

$ALEC

Date	Price Target	Rating	Analyst
12/14/2023	$8.00 → $15.00	Hold → Buy	Stifel
12/12/2023	$12.00	Buy	Deutsche Bank
9/25/2023	$4.00	Sell	Goldman
9/22/2023	$13.00	Overweight	Cantor Fitzgerald
1/6/2023	$24.00 → $12.00	Buy → Neutral	BofA Securities
9/9/2022	$27.00 → $13.00	Overweight → Equal-Weight	Morgan Stanley
7/7/2022	$15.00	Buy	Mizuho
4/13/2022	$9.00	Sell	Goldman

More analyst ratings

Alector to Host Mid-Year Earnings Conference Call

Chat with this insight

Recent Analyst Ratings for $ALEC

$ALEC SEC Filings

Alector Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Alector Inc.

Alector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ALEC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Alector Inc.

Amendment: SEC Form SC 13G/A filed by Alector Inc.

SEC Form SC 13G/A filed by Alector Inc. (Amendment)

$ALEC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Alector upgraded by Stifel with a new price target

Deutsche Bank initiated coverage on Alector with a new price target

Goldman initiated coverage on Alector with a new price target

$ALEC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Scheller Richard H was granted 15,833 shares, increasing direct ownership by 45% to 50,833 units (SEC Form 4)

Chief Financial Officer Grasso Marc was granted 216,400 shares, increasing direct ownership by 166% to 347,140 units (SEC Form 4)

Chief Executive Officer Rosenthal Arnon was granted 610,500 shares, increasing direct ownership by 31% to 2,559,246 units (SEC Form 4)

$ALEC Financials

Live finance-specific insights

$ALEC Press Releases

Fastest customizable press release news feed in the world

$ALEC Leadership Updates

Live Leadership Updates

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Alector to Host Mid-Year Earnings Conference Call

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Alector Reports First Quarter 2024 Financial Results and Provides Business Update

Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer

$ALEC Market Insights

Live Market Insights

Cantor Fitzgerald Reiterates Overweight on Alector

HC Wainwright & Co. Reiterates Buy on Alector, Maintains $35 Price Target

Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Recent Analyst Ratings for
$ALEC

$ALEC
SEC Filings

$ALEC
Large Ownership Changes

$ALEC
Analyst Ratings

$ALEC
Insider Trading

$ALEC
Financials

$ALEC
Press Releases

$ALEC
Leadership Updates

$ALEC
Market Insights